Eli Lilly along with POINT Biopharma Global, Inc. have declared a final agreement where Lilly will take over POINT, a company specializing in radiopharmaceuticals.

Alvotech along with Kashiv Biosciences LLC have publicized their exclusive licensing accord for AVT23 (also called ADL018).

ALX Oncology Holdings Inc. announced encouraging initial results from Phase 2 of its ASPEN-06 trial. The trial evaluates the use of its CD47 blocker, evorpacept, with trastuzumab, CYRAMZA®, and paclitaxel in treating HER2-positive gastric/gastroesophageal junction cancer patients.

Boehringer Ingelheim revealed that their interchangeable* biosimilar to Humira®, known as Adalimumab-adbm injection, is now available at a low wholesale acquisition cost.

Caliway Biopharmaceuticals announced successful primary and secondary endpoints of the phase 2 stage 2 trial for CBL-0202, outperforming placebo in ITT and PP groups.

The U.S. FDA has granted Priority Review to Rocket Pharmaceuticals, Inc. for their late-stage gene therapy, RP-L201 (marnetegragene autotemcel).

Presenting new preclinical data on LASN01 for treating TED, Lassen Therapeutics, a biotechnology firm engaged in clinical stages, is pioneering unique antibody therapeutics.

Kashiv BioSciences, LLC declared the start of enrollment for their Phase III clinical trial initiating with their first patient for their biosimilar candidate, ADL018, a potential alternative to XOLAIR®.

Nexcella Inc. revealed updates from its ongoing Phase 1b/2 NEXICART-1 trial on its proprietary BCMA-targeted CAR T cell treatment, NXC-201.

Novartis reported promising initial results from a 9-month interim assessment of the Phase III APPLAUSE-IgAN trial. The experimental factor B inhibitor, iptacopan, showed superior effectiveness in reducing proteinuria compared to placebo.

Biogen Inc. disclosed that the U.S. FDA provided their endorsement for TOFIDENCE (tocilizumab-bavi) in an intravenous format, a biosimilar monoclonal antibody that references ACTEMRA.

AbbVie shared Phase 3 CANOVA trial results for the VenDex combo in treating relapsed or resistant multiple myeloma in patients with two or more prior treatments.